Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Zymeworks BC Inc (NASDAQ: ZYME) closed at $12.28 in the last session, up 4.96% from day before closing price of $11.70. In other words, the price has increased by $4.96 from its previous closing price. On the day, 0.97 million shares were traded. ZYME stock price reached its highest trading level at $12.44 during the session, while it also had its lowest trading level at $11.82.
Ratios:
We take a closer look at ZYME’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.40 and its Current Ratio is at 3.40. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On November 07, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $10 to $25.
Wells Fargo Downgraded its Overweight to Equal Weight on November 01, 2024, while the target price for the stock was maintained at $12.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 16 ’25 when EcoR1 Capital, LLC bought 121,681 shares for $13.88 per share. The transaction valued at 1,689,541 led to the insider holds 15,700,413 shares of the business.
EcoR1 Capital, LLC bought 19,748 shares of ZYME for $273,998 on Jan 17 ’25. The Director now owns 15,720,161 shares after completing the transaction at $13.87 per share. On Jan 13 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 74,125 shares for $13.39 each. As a result, the insider paid 992,875 and bolstered with 15,485,203 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 854404288 and an Enterprise Value of 606807552. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.29 while its Price-to-Book (P/B) ratio in mrq is 2.52. Its current Enterprise Value per Revenue stands at 7.952 whereas that against EBITDA is -5.369.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.18, which has changed by 0.14020431 over the last 52 weeks, in comparison to a change of 0.087141395 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $7.97. The 50-Day Moving Average of the stock is -12.13%, while the 200-Day Moving Average is calculated to be -0.34%.
Shares Statistics:
According to the various share statistics, ZYME traded on average about 505.62K shares per day over the past 3-months and 858430 shares per day over the past 10 days. A total of 68.96M shares are outstanding, with a floating share count of 67.30M. Insiders hold about 4.07% of the company’s shares, while institutions hold 95.28% stake in the company. Shares short for ZYME as of 1740700800 were 3963020 with a Short Ratio of 7.84, compared to 1738281600 on 4380063. Therefore, it implies a Short% of Shares Outstanding of 3963020 and a Short% of Float of 7.39.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
